Kenneth E. Aldridge - Concepedia

Author

Kenneth E. Aldridge

University Medical Center New Orleans

Also Known As

K Aldridge, KENNETH E. ALDRIDGE, Kenneth Aldridge, Kenneth E Aldridge, Kenneth E. Aldridge

Publications

1.6K

Citations

H-Index

Concepts

All Affiliations

University Medical Center New Orleans Louisiana State University Louisiana State University Health Sciences Center New Orleans Indiana University – Purdue University Indianapolis University of Iowa

About

Kenneth E. Aldridge is an author at University Medical Center New Orleans specializing in medicine, clinical microbiology, and microbiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	13	407
2	Health Sciences	6	6	207
3	Engineering	1	1	47
4	Biology	1	1	47
5	Epidemiology	1	1	16

Kenneth E. Aldridge

Publications

1.1K

Citations

H-Index

Page 1

	Year	Citations
Association of Atopobium vaginae, a recently described metronidazole resistant anaerobe, with bacterial vaginosis Michael J. Ferris, Alicia Masztal, Kenneth E. Aldridge, BMC Infectious Diseases	2004	253
Multicenter Survey of the Changing In Vitro Antimicrobial Susceptibilities of Clinical Isolates of <i>Bacteroides fragilis</i> Group, <i>Prevotella, Fusobacterium, Porphyromonas</i> , and <i>Peptostreptococcus</i> Species Kenneth E. Aldridge, Deborah Ashcraft, K M Cambre, Antimicrobial Agents and Chemotherapy	2001	230
Bacteremia Due to <i>Bacteroides fragilis</i> Group: Distribution of Species, β-Lactamase Production, and Antimicrobial Susceptibility Patterns Kenneth E. Aldridge, Deborah Ashcraft, Megan O’Brien, Antimicrobial Agents and Chemotherapy	2002	71
Comparison of the in vitro activity of ciprofloxacin and 24 other antimicrobial agents against clinical strains of Chromobacterium violaceum Kenneth E. Aldridge, Gregory T. Valainis, Charles V. Sanders Diagnostic Microbiology and Infectious Disease Antimicrobial SusceptibilityHealth SciencesAntibioticsOther Antimicrobial AgentsAntibacterial Agent	1988	67
Piperacillin/tazobactam (YTR 830) combination. Comparative antimicrobial activity against 5889 recent aerobic clinical isolates and 60 Bacteroides fragilis group strains. Ronald N. Jones, Michael A. Pfaller, Peter Fuchs, PubMed	1990	56
Comparison of Micro-ID, API 20E, and Conventional Media Systems in Identification of <i>Enterobacteriaceae</i> Kenneth E. Aldridge, Becky B. Gardner, Stephen J. Clark, Journal of Clinical Microbiology EngineeringPathogen DetectionBacterial PathogensBioanalysisNew Identification Kit	1978	47
Piperacillin/tazobactam (YTR 830) combination Ronald N. Jones, Michael A. Pfaller, Peter Fuchs, Diagnostic Microbiology and Infectious Disease Medicinal ChemistryYtr 830MedicineMechanism Of ActionPharmacotherapy	1989	41
The rapid emergence of fluoroquinolone-methicillin-resistant Staphylococcus aureus infections in a community hospital Kenneth E. Aldridge, Mikhail S. Gelfand, Denise D. Schiro, Diagnostic Microbiology and Infectious Disease Health SciencesAntibioticsDrug ResistanceHealthcare-associated InfectionRapid Emergence	1992	40
A five-year multicenter study of the susceptibility of the Bacteroides fragilis group isolates to cephalosporins, cephamins, penicillins, clindamycin, and metronidazole in the United States Kenneth E. Aldridge, L. Barth Reller, Leona W. Ayers, Diagnostic Microbiology and Infectious Disease Pathogenic MicrobiologyHealth SciencesAntibioticsFive-year Multicenter StudyMedicine	1994	40
In Vitro Susceptibilities of the <i>Bacteroides fragilis</i> Group Species: Change in Isolation Rates Significantly Affects Overall Susceptibility Data Kenneth E. Aldridge, Megan O’Brien Journal of Clinical Microbiology	2002	35

Page 1